abstract |
The present invention relates to the administration of human apolipoprotein A-IV, isoforms and active fragments thereof, to humans as an injectable formulation for the purpose of controlling appetite and reducing food intake and body weight. The invention is also directed to an injectable pharmaceutical formulation of human apolipoprotein A-IV, or active fragments thereof. |